Cellectis (the 'Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV- study presented today at ASGCT 2026 Annual Meeting along with initial ...

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology ...

(Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin ...

Life Sciences Revenue -- $1.6 million, decreasing 48.4%, with R2 segment revenue mainly impacted by declines in Glacial FX ...

Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global ...

Wednesday, May 13, 2026, at 4:30 p.m. ET Pro forma revenue (prostate cancer operations) -- $23.9 million, an 11% increase, ...

Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026.

Q1 2026 Management View "Karyopharm continues to execute through an important period for the company with recent and upcoming milestones that we believe can unlock meaningful growth opportunities and ...

The resignation of Santa Fe’s Alternative Response Unit manager leaves the program with five employees as concerns grow over ...

A significant number of cancer patients—particularly those with more advanced cancers who are more likely to receive care at ...